The purpose is to discuss advances in the nutritional and pharmacological management of phenylketonuria (PKU).
INTRODUCTION
Phenylketonuria (PKU, OMIM 261600), an autosomal recessive disorder of phenylalanine (phe) metabolism, is the first human genetic disease to have effective programs for newborn screening and treatment. The average incidence of PKU in the USA is 1 : 12 707 live births, with an estimated 14 988 individuals with PKU diagnosed from 1965 to 2010 [1 && ]. PKU is caused by a deficiency of hepatic phenylalanine hydroxylase (PAH, EC 1. 14.16 .1) activity that catalyzes the conversion of phe to tyrosine in a reaction dependent on the PAH cofactor tetrahydrobiopterin (BH 4 ; sapropterin dihydrochloride; Fig. 1 ) [2] . Tyrosine becomes an indispensable amino acid in PKU. Over 900 mutations in the PAH gene have been identified, and most individuals with PKU are compound heterozygotes (www.biopku.org). With normal intake of dietary protein, phe accumulates in the blood leading to toxic levels of phe in the brain and profound cognitive impairment. A lifelong lowphe diet remains the mainstay of PKU management, reducing phe levels and protecting brain development. A comprehensive review indicates moderate evidence for a threshold effect of a phe level of more than 400 mmol/l associated with intelligence quotients (IQs) of below 85 (Fig. 2) [3 && ]. Recommended treatment for individuals with PKU of all ages includes a low-phe diet with goal blood phe concentration between 120 and 360 mmol/l [4 && ]. The lowphe diet for individuals with classical PKU restricts protein intake from natural foods to 5-10 g protein per day (250-500 mg phe) and for nutritional adequacy requires a phe-free amino acid medical formula (24-32 oz per day), providing over 80% of protein and energy needs [5] . Lifelong compliance with the diet is challenging and poor control of blood phe levels [6] results in neuropsychological deterioration and increased risk of congenital anomalies in children born to mothers with PKU [7 & ]. Although intellectual development is near normal with implementation of the low-phe diet shortly after birth, there is evidence of suboptimal health outcomes in PKU patients treated with the amino acid diet including neurocognitive impairments such as poor executive function skills and psychiatric problems [8] , skeletal fragility [9] , and impaired renal function [10] . Improved options for nutritional management and adjuvant therapy are needed to improve health outcomes for individuals with PKU. The purpose of this review is to discuss the following: advances in the nutritional management of PKU using glycomacropeptide (GMP), new evidence regarding the cause of skeletal fragility in PKU, supplementation with large
KEY POINTS
PKU results from mutations in the PAH gene that in concert with the essential cofactor BH 4 converts phe to tyrosine.
A low-phe diet that restricts intake of natural protein and requires a phe-free amino acid medical formula is the mainstay of PKU management, reducing phe levels and preventing cognitive impairment.
Food products made with GMP, a low-phe whey protein, provide an alternative to amino acid formula for the nutritional management of PKU.
Skeletal fragility has emerged as a poorly understood but common complication of treated PKU that shows no consistent association with blood phe levels.
New adjunct therapies for PKU include drug treatment with the cofactor BH 4 to enhance residual PAH activity, and supplementation with large neutral amino acids to decrease phe levels by competing with phe for shared amino acid transporters. CH COOH HO FIGURE 1. Phenylalanine (phe) metabolism in phenylketonuria (PKU). As indicated by the 'X', PKU results from mutations (over 900 have been identified) that affect the hepatic phenylalanine hydroxylase (PAH) enzyme needed for the hydroxylation of the indispensable amino acid phe to tyrosine. PKU may also result from mutations in genes involved in recycling the essential PAH cofactor tetrahydrobiopterin. Due to these mutations which reduce the conversion of phe to tyrosine, phe accumulates in blood and is transaminated and decarboxylated into many compounds which appear in blood and urine; three of the compounds which are measured clinically are shown. Tyrosine, a precursor for multiple biological products, becomes an indispensable amino acid (AA) and must be provided by the diet for those with PKU. Under physiological conditions, PAH catalyzes about 75% of the phe input from the diet and protein catabolism.
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GLYCOMACROPEPTIDE PROVIDES A SOURCE OF LOW-PHENYLALANINE INTACT PROTEIN FOR PHENYLKETONURIA
GMP occurs naturally in bovine milk within the whey fraction, and is the only known dietary protein that contains no phe. Thus, GMP provides a source of low-phe intact protein that is an alternative to synthetic amino acids in the PKU diet. GMP is a polar glycophosphopeptide comprising 64 amino acids whose unique amino acid profile includes an absence of the aromatic amino acids, phe, tryptophan, and tyrosine, and higher concentrations of isoleucine and threonine than those found in other dietary proteins [11] . Commercial GMP is a by-product of cheese production and is used as a food ingredient for a variety of applications [11] . Highly purified GMP containing less than 2.0 mg phe per gram of protein is required for formulation of GMP medical foods for PKU. Sensory studies in individuals with PKU indicate that GMP medical foods are acceptable alternatives to amino acid medical foods, and, in general, improve taste and variety in the PKU diet [7 & ,12] .
To provide a complete source of protein for individuals with PKU, GMP is supplemented with arginine, histidine, leucine, tyrosine, and tryptophan [13] . Studies in the murine model of PKU (Pah enu2 ) demonstrate that GMP supplemented with limiting indispensable amino acids provides an adequate source of protein that supports growth and accretion of lean body mass with the benefit of reduced body fat mass and an apparent increase in fat oxidation [14, 15] . The antiobesity effects of GMP are relevant, as females with PKU have a greater incidence of overweight and obesity compared with US children [16] .
Evidence from studies in murine and human PKU indicates that GMP is a more physiologic source of low-phe dietary protein compared with synthetic amino acids [7 & ,12] . The salient feature is that GMP medical foods provide predominantly 'intact' protein (less than 35% supplemental amino acids) compared with amino acid medical foods which provide 100% free amino acids and a typical Western diet which provides less than 10% free amino acids. Greater protein synthesis and N retention are observed with ingestion of intact protein compared with a mixture of single amino acids. Therefore, GMP consumption mimics ingestion of intact proteins due to slower absorption and decreased Probability of intelligence quotient (IQ) below 85 at varying blood phenylalanine (phe) levels and phe measurement times. Blood phe levels were historical, that is, measured more than 1 year prior to IQ testing in children before age 6 or at or after age 6. There is moderate evidence for a threshold effect of a phe level of 400 mmol/l associated with IQs below 85. The probability of having an IQ below 85 does not increase considerably above a blood phe level of 2000 mmol/l. Adapted with permission from [3 && ].
hepatic degradation of dietary intact protein compared with free amino acids [17] . Similar benefits were observed in an inpatient study of 11 PKU patients. The GMP diet showed significantly higher postprandial plasma amino acid concentrations and a trend for higher insulin concentration, suggesting slower amino acid absorption after a meal, and significantly lower blood urea concentration, suggesting decreased ureagenesis, compared with the amino acid diet [13] . Postprandial plasma phe concentrations were not different with the amino acid and GMP diets, but fasting phe levels tended to be lower with the GMP diet, suggesting less daily variation in phe concentration. Evidence also suggests that GMP promotes satiety in those with PKU, based on greater subjective feelings of fullness and decreased postprandial plasma ghrelin concentration [18] . In summary, GMP might improve dietary compliance and reduce phe levels [12] . Further studies in PKU patients are underway to evaluate metabolic and nutritional features of the low-phe GMP and amino acid diets (www.clinical trials.gov NCT 01428258).
SKELETAL FRAGILITY IS A CHRONIC, POORLY UNDERSTOOD COMPLICATION OF PHENYLKETONURIA
Skeletal fragility is a chronic complication of treated PKU. Compared to siblings, and age and sexmatched controls, patients with PKU have lower bone mineral density (BMD) [9] and lower bone mineral content, suggesting a higher lifetime fracture risk. In the only study to evaluate fracture rates, individuals with PKU had higher fracture rates after age 8 compared to sibling controls, suggesting that fractures could relate to higher phe levels [19] . However, the pathophysiology of skeletal fragility in PKU is unknown. Cross-sectional studies show no consistent relationships between BMD and blood phe levels [9] , vitamin D levels [9, 20] , nutrient intake [20, 21] , and physical activity [22] . Longitudinal studies are needed to determine the pathogenesis of the PKU skeletal phenotype, permitting clinicians to recommend appropriate therapy to help individuals with PKU to achieve and maintain optimal bone biomechanical performance and prevent fractures.
A critical question is whether the skeletal fragility in PKU is inherent to the genotype or its management with the low-phe, synthetic amino acid diet. This question cannot be addressed in humans, since the low-phe amino acid diet must be followed for life to prevent neurologic sequelae including cognitive impairment. Evidence from a long-term factorial experiment in wild-type and Pah enu2 mice answered this question -both the PKU genotype and the amino acid diet contribute to the PKU bone phenotype [23 && ]. Regardless of diet and sex, PKU mice showed global deficits in BMD and bone biomechanical performance, resulting in brittle, weak femora compared to wild-type littermates (Fig. 3 ). It is important to note that the bone deficit in the PKU mice is global. Stiffness, strength, and brittleness are all adversely affected by the disease. The increased bone brittleness in murine PKU strongly suggests that the disease results in the production of abnormal bone matrix protein as well as abnormal mineralization. Moreover, the amino acid diet resulted in smaller femora with reduced crosssectional area and reduced strength, reflected in reduced maximal load tolerated before fracture, in both PKU and wild-type mice compared with the GMP diet [23 && ]. The observation of smaller and weaker femora in both wild-type and PKU mice fed an amino acid diet strongly suggests that the amino acid diet prevents optimal bone development. Radial bone growth is a homeostatically regulated process that is believed to maintain strain, or fractional changes in bone length that result from mechanical loading, within a narrow range over the course of usual activities [24, 25] . This model successfully accounts for the anabolic effects of skeletal loading, the catabolic effects of skeletal unloading, and the bone growth response to disorders in which the tissue-level mechanical performance of bone is impaired. Moreover, bone size is a major determinant of bone strength [24, 25] , so failure to achieve normal bone size increases the risk of subsequent fracture.
There are several possible explanations for the detrimental effects of the amino acid diet on bone. Impaired biosynthesis of the bone matrix protein collagen due to poor retention and subtle deficiencies of amino acids required for collagen synthesis, such as glycine, proline, and lysine, may occur. Collagen cross-link formation, maturation, and chemistry may be altered, thus reducing the tensile strength of the bone matrix [26] . Chronic ingestion of an amino acid diet may also result in, alterations in substrate utilization for energy balance [27] . A recent report indicating impaired renal function in PKU [10] may lead to alterations in vitamin D metabolism and calcium balance. Finally, the high dietary acid load of the amino acid diet might affect optimal bone development. All of these effects associated with the amino acid diet may have a negative effect on bone health.
Manz et al. [28] recognized metabolic acidosis as a complication of the synthetic amino acid diet in 1977. Surprisingly, no investigators have subsequently assessed whether the acidic amino acid diet contributes to PKU-related osteoporosis. In an inpatient metabolic study, the amino acid diet introduced a greater dietary potential renal acid load and evoked adaptations consistent with compensated metabolic acidosis based on reduced serum bicarbonate levels, compared with the GMP diet [13] . In humans, a high dietary acid load adversely affects skeletal health due to bone buffering of H þ ions, evoking increased bone resorption and renal calcium excretion with lower BMD [29, 30] . Support for the acid load hypothesis comes from a recent study of 67 individuals with PKU, which reported hypercalciuria in nearly one-quarter of participants [10] . In a randomized, placebo-controlled trial of 201 older adults without PKU [31] , neutralizing dietary acid load with potassium citrate for 24 months increased areal spine BMD and increased trabecular density in the extremities. Additional research is needed to evaluate whether the high dietary acid load conferred by the amino acid diet contributes to skeletal fragility by increasing bone resorption and renal calcium excretion in people with PKU.
Among young adults with PKU treated since birth with an amino acid diet, increasing dietary protein intake was associated with decreasing glomerular filtration rate (r ¼ À0.41, P ¼ 0.003) [10] . Reduced renal function in PKU could decrease renal 1,25(OH) 2 D synthesis and reduce fractional calcium absorption, leading to a decline in BMD. Taken together, the amino acid diet provides a high dietary acid load and might also impair renal function [32] , resulting in multiple negative effects on bone health. The pathophysiology of skeletal fragility in PKU is an important topic for future investigation.
SUPPLEMENTATION WITH LARGE NEUTRAL AMINO ACIDS MAY COMPETITIVELY INHIBIT PHENYLALANINE TRANSPORT
Large neutral amino acids are dietary supplements prescribed for adults with PKU who cannot adhere to a low-phe diet [33] . The rationale is that LNAAs may decrease concentrations of phe in blood and brain by competitive inhibition of phe transport across the intestinal mucosa and blood- transporter expressed in brain has a high affinity for phe, and this, in combination with 2-10-fold higher concentrations of phe relative to other LNAAs in blood, results in excess transport of phe into the brain, which is generally considered neurotoxic [8] . Moreover, concentrations of the nonphe LNAAs are decreased, reducing synthesis of essential brain proteins such as the neurotransmitters dopamine and serotonin, due to limited availability of their respective tyrosine and tryptophan precursors [36] . Specific supplementation with tyrosine and tryptophan improved metabolism of dopamine and serotonin in PKU patients; however, later studies with larger doses of tyrosine and tryptophan did not show positive results [33] . Moreover, evidence that LNAA supplementation increases melatonin, a serotonin metabolite, suggests that levels of melatonin in blood and urine may serve as an accessible biomarker reflecting brain serotonin synthesis in patients with PKU [35 & ]. Additional surrogate biomarkers reflecting the metabolic effects of brain phe are needed to complement blood phe levels, thereby assisting with assessment of metabolic control of PKU.
The concept of competitive inhibition of phe transport underlying supplementation with LNAAs is being applied to nonphysiological amino acids. Studies in Pah enu2 mice provide support for the use of a variety of nonphysiological amino acids to act as competitive inhibitors of brain amino acid transporters, resulting in reduced brain phe concentrations with minimal impact on other downstream intermediates [34 & ]. Limited evidence supports the efficacy of LNAA supplementation to reduce blood phe levels and improve cognitive outcomes. Three short-term studies addressed the effects of LNAAs in a total of 47 participants using dosages ranging from 250 mg to 1 g LNAA/kg/day [3 && ]. One study noted negative nitrogen balance in four individuals taking LNAAs (0.8 g/kg/day) and consuming natural protein (0.6 g/kg/day) without amino acid formula [37] . Individuals with phe levels above 1000 mmol/l showed 25-39% decreases in plasma phe levels, and one randomized controlled study reported a positive effect of LNAA on executive functions [38] . In summary, LNAA supplementation, either alone or in combination with a low-phe diet, has potential to improve health outcomes for individuals unable to follow the low-phe diet. However, current evidence for the efficacy of LNAA supplementation cannot be considered as more than proof-of-concept; additional research is needed to demonstrate that LNAAs provide a viable approach for reducing phe levels or increasing dietary phe tolerance [3 && ], without adversely affecting renal and bone health.
PHARMACOLOGIC TREATMENT WITH TETRAHYDROBIOPTERIN ACTING AS A MOLECULAR CHAPERONE INCREASES DIETARY PHENYLALANINE TOLERANCE FOR SOME WITH PHENYLKETONURIA
Tetrahydrobiopterin is an essential cofactor for nitric oxide synthases and three aromatic amino acid hydroxylase enzymes -PAH, tyrosine hydroxylase, and tryptophan hydroxylase. In about 20-30% of PKU patients, phe levels may be controlled through pharmacologic treatment with BH 4 [39 & ]. Sapropterin dihydrochloride (Kuvan), the synthetic form of BH 4, was approved for the treatment of patients with BH 4 -responsive PKU in combination with diet by the US Food and Drug Administration in 2007 and the European Medicines Agency in 2008 [40] . In general, patients with the milder PKU phenotypes have a higher response rate to BH 4 than those with low dietary phe tolerance. Patient genotypes can help predict BH 4 responsiveness. A database is available listing PAH mutations and patients/genotypes, and their reported response to BH 4 (www.biopku.org). An oral challenge with BH 4 (20 mg/kg/day for 2 days or 1-3 weeks) can identify those with BH 4 -responsive PKU; a 30% decrease in blood phe level compared to the basal value is a positive response [39 & ]. For a patient to respond to BH 4 , sufficient residual liver PAH protein must be present to interact with BH 4 . Clinical BH 4 responsiveness is usually determined by the presence of a single BH 4 -responsive mutation with at least 25% residual PAH activity, although there are exceptions depending on interallelic complementation within the genotype [39 & ]. BH 4 increases residual PAH activity by acting as a molecular chaperone to stabilize partially misfolded PAH proteins. BH 4 also affects PAH enzyme kinetics as illustrated by different responses to BH 4 , depending on baseline phe concentration and the BH 4 dose administered in patients with the same genotype [41] .
Tetrahydrobiopterin therapy significantly reduced phe levels compared to placebo in two randomized controlled trials and two open-label trials, without significant adverse effects [3 && ]. In positive responders, baseline phe tolerance may increase 2-4-fold permitting an additional 400-1000 mg of dietary phe each day, and allowing the addition of 2-3 servings of typical bread and cereal products in place of low-protein products. However, few individuals with PKU can achieve a completely liberalized diet, and low-phe medical foods are almost always required for nutritional adequacy. A retrospective study of 147 patients with both mild and classic PKU treated with BH 4 and followed for over 10 years indicated that 47% of patients reported improvement in dietary adherence and 63% reported improved adherence to treatment [40] . The potential effects of BH 4 on long-term health outcomes such as cognition, executive function, and quality of life have not been established, and studies are ongoing. Overall, the strength of the evidence for a large, positive effect of BH 4 on reducing phe levels and improving metabolic control over the short term in some PKU groups is moderate [3 && ].
CONCLUSION
A low-phe diet remains the cornerstone of PKU management. GMP medical foods improve taste and variety, and provide a more physiologically normalized source of intact protein that might improve bone health compared with synthetic amino acids. Adjuvant pharmacologic therapy with BH 4 allows some individuals with PKU to liberalize their diet. Long-term outcome studies assessing efficacy and safety of BH 4 , LNAA supplementation, and GMP medical foods are needed. Emerging therapeutic approaches are currently in preclinical and clinical trials including PAH enzyme substitution with phe ammonia lyase joined with polyethylene glycol (PEG-PAL) [39 & ], hepatocyte repopulation, and gene therapy. The future holds promise for new options to allow PKU patients to liberalize their diet and still improve lifelong metabolic control.
